Goldman Sachs is making sector-wide changes in ratings for health-care companies saying stock selection will be key ahead of 2024.
- Analysts led by
Asad Haider provide their outlook for the new yearm expecting life sciences tools to outperform in 2024 and note a tougher backdrop for managed care and dental companies. - Among life science tools & diagnostics stocks, the broker upgrades QIAGEN N.V. to buy from neutral, saying defensive end markets could outperform in the first half of 2024 before a broader recovery in the later half; PT to $50 from $47 (QGEN +0.3%)
- Downgrades Danaher to neutral from buy ...
- Downgrades Danaher to neutral from buy ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.